Artificial liver device tested in humans for first time
NCT ID NCT06285253
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a device called miroliverELAP, which uses a bioengineered liver graft to filter blood outside the body, in 10 adults with acute liver failure. The goal was to check safety and see if it can support the liver for up to 48 hours, giving time for recovery or a transplant. Results are not yet available, but the study is complete.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- bioengineered liver graft (miroliverELAP)
- What this could lead to
- If successful, this device could provide temporary liver support for patients with acute liver failure, giving the liver time to heal or bridging to a transplant.
- What could go wrong
- This is a very early phase 1 trial with only 10 participants, focused on safety. The device may not work as hoped, and there are risks of serious side effects from the blood-circulation procedure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
10 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Jan 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. 18 years to 80 years old at the time of signing the informed consent 2. Subject must: 1. be deemed competent to consent by an independent qualified practitioner, or 2. have consent given by a Legally Authorized Representative 3. Subject should be in the intensive care unit 4. Be diagnosed with 4.1. Acute Liver Failure defined as: 1. INR ≥ 2.0, and 2. Hepatic Encephalopathy Grade II-III (West Haven Criteria), and 3. Less than 4 weeks (28 days) of disease duration 4.2. Severe Acute Alcohol-Associated Hepatitis as defined as: <!-- --> 1. Hepatic Encephalopathy Grade I-III (West Haven Criteria), and 2. Model for End-Stage Liver Disease (MELD) Score ≥ 20, and 3. INR ≥ 2.0, and 4. No overt evidence of cirrhosis 4.3. Acute on Chronic Liver Failure: <!-- --> 1. Hepatic Encephalopathy Grade I-III (West Haven Criteria), and 2. Model for End-Stage Liver Disease (MELD) Score ≥ 20, and 3. INR ≥ 2.0, 5\. Subject is not a candidate for liver transplant and will not become a candidate in the event of worsening conditions. Exclusion Criteria 1. Grade IV West Haven Encephalopathy Criteria 2. Previous liver transplant 3. Currently requires chronic hemodialysis (CRRT or other forms of continuous renal replacement are allowed). 4. Uncontrolled documented infection, hypotension, or refractory shock. This is defined as a need for a single vasopressor, or combination of vasopressors, that exceed a norepinephrine equivalent of 0.5 mcg/kg/min. 5. Liver injury due to trauma 6. Any current liver cancer 7. Currently on medications with a narrow therapeutic index 8. Platelet count \< 40,000 μL 9. If the subject is intubated and has an acute lung injury 10. Experiencing a bleeding event, defined as: 1. Active gastrointestinal or other overt bleeding event, or 2. Hemoglobin drop \> 3g/dL within the past 24 hours, or 3. Received ≥ 3 units of red blood cell transfusion within the past 24 hours 11. Female that is currently pregnant, planning to be pregnant, or currently breastfeeding 12. Refusal to receive blood products
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute alcoholic hepatitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Intermountain Healthcare
Salt Lake City, Utah, 84103, United States
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
-
Mount Sinai Recanati/Miller Transplantation Institute
New York, New York, 10029, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
University of Michigan Medical School
Ann Arbor, Michigan, 48109, United States
-
University of Minnesota Medical School
Minneapolis, Minnesota, 55455, United States
-
Virginia Commonwealth University Medical Center
Richmond, Virginia, 23970, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo keep cirrhosis patients out of the hospital?
- Can viral markers predict who survives hepatitis b liver failure?
- Can a common antioxidant rescue failing livers?
- Better crystal ball for liver crisis: new scores put to the test
- Scientists hunt for clues in body fluids to predict liver failure outcomes
- Liver failure treatment MARS: does it help avoid transplants?